2-{2-[(4aS,5R)-4a-ethyl-5-hydroxy-1-phenyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl]-1-hydroxyethyl}pyridine-4-carbonitrile | 1299473-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-{2-[(4aS,5R)-4a-ethyl-5-hydroxy-1-phenyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl]-1-hydroxyethyl}pyridine-4-carbonitrile
• 英文别名: 2-[2-[(4aS,5R)-4a-ethyl-5-hydroxy-1-phenyl-6,7-dihydro-4H-cyclopenta[f]indazol-5-yl]-1-hydroxyethyl]pyridine-4-carbonitrile
• CAS: 1299473-87-2
• 化学式: C₂₆H₂₆N₄O₂
• 分子量: 426.518
• InChiKey: NXEJCCNUYVFPGU-XBCLTQTASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  95
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS 2-[1-PHÉNYL-5-HYDROXY-4A-SUBSTITUÉS-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ÉTHYL PHÉNYLÉS COMME LIGANDS DES RÉCEPTEURS AUX GLUCOCORTICOÏDES
  申请人：MERCK SHARP & DOHME

  公开号：WO2011053574A1

  公开（公告）日：2011-05-05

  The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖了Formula I的化合物，或其药用可接受的盐或水合物，这些化合物可作为选择性糖皮质激素受体配体，用于治疗各种自身免疫和炎症性疾病或症状。药物组合物和使用方法也包括在内。
• 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
  申请人：Bungard Christopher James

  公开号：US20120214847A1

  公开（公告）日：2012-08-23

  The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖以下化合物：公式I的化合物或其药学上可接受的盐或水合物，其可用作选择性糖皮质激素受体配体，用于治疗各种自身免疫性和炎症性疾病或病况。还包括药物组合物和使用方法。